Transforming Growth Factor-beta 1 is a Heparin-binding Protein: Identification of Putative Heparin-binding Regions and Isolation of Heparins with Varying Affinity for TGF-beta 1
Overview
Physiology
Authors
Affiliations
Previous studies indicated that a major factor in heparin's ability to suppress the proliferation of vascular smooth muscle cells is an interaction with transforming growth factor-beta 1 (TGF-beta 1). Heparin appeared to bind directly to TGF-beta 1 and to prevent the association of TGF-beta 1 with alpha 2-macroglobulin (alpha 2-M). The present studies indicate that 20-70% of iodinated TGF-beta 1 binds to heparin-Sepharose and the retained fraction is eluted with approximately 0.37 M NaCl. Native, unlabelled platelet TGF-beta 1, however, is completely retained by heparin-Sepharose and eluted with 0.9-1.2 M NaCl. Using synthetic peptides, the regions of TGF-beta 1 that might be involved in the binding of heparin and other polyanions were examined. Sequence analysis of TGF-beta 1 indicated three regions with a high concentration of basic residues. Two of these regions had the basic residues arranged in a pattern homologous to reported consensus heparin-binding regions of other proteins. The third constituted a structurally novel pattern of basic residues. Synthetic peptides homologous to these three regions, but not to other regions of TGF-beta 1, were found to bind to heparin-Sepharose and were eluted with 0.15 M-0.30 M NaCl. Only two of these regions were capable of blocking the binding of heparin to 125I-TGF-beta. Immobilization of these peptides, followed by affinity purification of heparin, indicated that one peptide was capable of isolating subspecies of heparin with high and low affinity for authentic TGF-beta 1. The ability of TGF-beta 1 to bind to heparin or related proteoglycans under physiological conditions may be useful in understanding the biology of this pluripotent growth and metabolic signal. Conversely, a subspecies of heparin molecules with high affinity for TGF-beta 1 may be a factor in some of the diverse biological actions of heparin.
Sulfated and Phosphorylated Agarose as Biomaterials for a Biomimetic Paradigm for FGF-2 Release.
Forget A, Shastri V Biomimetics (Basel). 2025; 10(1).
PMID: 39851728 PMC: 11761575. DOI: 10.3390/biomimetics10010012.
Myeloid deficiency of heparan sulfate 6-O-endosulfatases impairs bone marrow hematopoiesis.
Whitehead A, Wang Z, Boustany R, Vives R, Lazartigues E, Liu J Matrix Biol. 2024; 134:107-118.
PMID: 39368561 PMC: 11585435. DOI: 10.1016/j.matbio.2024.10.002.
Tumor glucose metabolism and the T cell glycocalyx: implication for T cell function.
Schuurmans F, Wagemans K, Adema G, Cornelissen L Front Immunol. 2024; 15:1409238.
PMID: 38881904 PMC: 11176483. DOI: 10.3389/fimmu.2024.1409238.
Brown N, Ellerbe L, Hollister S, Temenoff J Ann Biomed Eng. 2024; 52(8):2287-2307.
PMID: 38734845 DOI: 10.1007/s10439-024-03530-z.
Heparan sulfates and heparan sulfate proteoglycans in hematopoiesis.
Piszczatowski R, Bulow H, Steidl U Blood. 2024; 143(25):2571-2587.
PMID: 38639475 PMC: 11830984. DOI: 10.1182/blood.2023022736.